In an effort to personalize medicine, the AGO explicitly supports all innovative steps that promote the use of new technologies such as “next generation sequencing” to test for not only the two most common mutated genes, BRCA1 and BRCA2, but also other genes involved in the homologous recombination repair of DNA as well as other relevant genes for ovarian cancer biology. This evidence concerns the gene BRCA2 and ovarian cancer.